Molecular changes consistent with increased proliferation and invasion are common in rectal cancer
Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene...
Ausführliche Beschreibung
Autor*in: |
Hughes, Rebecca [verfasserIn] Parry, James [verfasserIn] Beynon, John [verfasserIn] Jenkins, Gareth [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2011 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
Enthalten in: Revista de oncología - Barcelona : Doyma, 2000, 13(2011), 10 vom: Okt., Seite 753-759 |
---|---|
Übergeordnetes Werk: |
volume:13 ; year:2011 ; number:10 ; month:10 ; pages:753-759 |
Links: |
---|
DOI / URN: |
10.1007/s12094-011-0728-4 |
---|
Katalog-ID: |
SPR024256722 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR024256722 | ||
003 | DE-627 | ||
005 | 20230519111106.0 | ||
007 | cr uuu---uuuuu | ||
008 | 201006s2011 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12094-011-0728-4 |2 doi | |
035 | |a (DE-627)SPR024256722 | ||
035 | |a (SPR)s12094-011-0728-4-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
100 | 1 | |a Hughes, Rebecca |e verfasserin |4 aut | |
245 | 1 | 0 | |a Molecular changes consistent with increased proliferation and invasion are common in rectal cancer |
264 | 1 | |c 2011 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer. | ||
650 | 4 | |a Rectal cancer |7 (dpeaa)DE-He213 | |
650 | 4 | |a Molecular changes |7 (dpeaa)DE-He213 | |
650 | 4 | |a Neoadjuvant therapy |7 (dpeaa)DE-He213 | |
700 | 1 | |a Parry, James |e verfasserin |4 aut | |
700 | 1 | |a Beynon, John |e verfasserin |4 aut | |
700 | 1 | |a Jenkins, Gareth |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Revista de oncología |d Barcelona : Doyma, 2000 |g 13(2011), 10 vom: Okt., Seite 753-759 |w (DE-627)385985452 |w (DE-600)2143451-7 |x 1578-195X |7 nnns |
773 | 1 | 8 | |g volume:13 |g year:2011 |g number:10 |g month:10 |g pages:753-759 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12094-011-0728-4 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_120 | ||
912 | |a GBV_ILN_152 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_187 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_250 | ||
912 | |a GBV_ILN_281 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_702 | ||
951 | |a AR | ||
952 | |d 13 |j 2011 |e 10 |c 10 |h 753-759 |
author_variant |
r h rh j p jp j b jb g j gj |
---|---|
matchkey_str |
article:1578195X:2011----::oeuacagsossetihnraepoieainnivso |
hierarchy_sort_str |
2011 |
publishDate |
2011 |
allfields |
10.1007/s12094-011-0728-4 doi (DE-627)SPR024256722 (SPR)s12094-011-0728-4-e DE-627 ger DE-627 rakwb eng 610 ASE Hughes, Rebecca verfasserin aut Molecular changes consistent with increased proliferation and invasion are common in rectal cancer 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer. Rectal cancer (dpeaa)DE-He213 Molecular changes (dpeaa)DE-He213 Neoadjuvant therapy (dpeaa)DE-He213 Parry, James verfasserin aut Beynon, John verfasserin aut Jenkins, Gareth verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 13(2011), 10 vom: Okt., Seite 753-759 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:13 year:2011 number:10 month:10 pages:753-759 https://dx.doi.org/10.1007/s12094-011-0728-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 13 2011 10 10 753-759 |
spelling |
10.1007/s12094-011-0728-4 doi (DE-627)SPR024256722 (SPR)s12094-011-0728-4-e DE-627 ger DE-627 rakwb eng 610 ASE Hughes, Rebecca verfasserin aut Molecular changes consistent with increased proliferation and invasion are common in rectal cancer 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer. Rectal cancer (dpeaa)DE-He213 Molecular changes (dpeaa)DE-He213 Neoadjuvant therapy (dpeaa)DE-He213 Parry, James verfasserin aut Beynon, John verfasserin aut Jenkins, Gareth verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 13(2011), 10 vom: Okt., Seite 753-759 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:13 year:2011 number:10 month:10 pages:753-759 https://dx.doi.org/10.1007/s12094-011-0728-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 13 2011 10 10 753-759 |
allfields_unstemmed |
10.1007/s12094-011-0728-4 doi (DE-627)SPR024256722 (SPR)s12094-011-0728-4-e DE-627 ger DE-627 rakwb eng 610 ASE Hughes, Rebecca verfasserin aut Molecular changes consistent with increased proliferation and invasion are common in rectal cancer 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer. Rectal cancer (dpeaa)DE-He213 Molecular changes (dpeaa)DE-He213 Neoadjuvant therapy (dpeaa)DE-He213 Parry, James verfasserin aut Beynon, John verfasserin aut Jenkins, Gareth verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 13(2011), 10 vom: Okt., Seite 753-759 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:13 year:2011 number:10 month:10 pages:753-759 https://dx.doi.org/10.1007/s12094-011-0728-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 13 2011 10 10 753-759 |
allfieldsGer |
10.1007/s12094-011-0728-4 doi (DE-627)SPR024256722 (SPR)s12094-011-0728-4-e DE-627 ger DE-627 rakwb eng 610 ASE Hughes, Rebecca verfasserin aut Molecular changes consistent with increased proliferation and invasion are common in rectal cancer 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer. Rectal cancer (dpeaa)DE-He213 Molecular changes (dpeaa)DE-He213 Neoadjuvant therapy (dpeaa)DE-He213 Parry, James verfasserin aut Beynon, John verfasserin aut Jenkins, Gareth verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 13(2011), 10 vom: Okt., Seite 753-759 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:13 year:2011 number:10 month:10 pages:753-759 https://dx.doi.org/10.1007/s12094-011-0728-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 13 2011 10 10 753-759 |
allfieldsSound |
10.1007/s12094-011-0728-4 doi (DE-627)SPR024256722 (SPR)s12094-011-0728-4-e DE-627 ger DE-627 rakwb eng 610 ASE Hughes, Rebecca verfasserin aut Molecular changes consistent with increased proliferation and invasion are common in rectal cancer 2011 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer. Rectal cancer (dpeaa)DE-He213 Molecular changes (dpeaa)DE-He213 Neoadjuvant therapy (dpeaa)DE-He213 Parry, James verfasserin aut Beynon, John verfasserin aut Jenkins, Gareth verfasserin aut Enthalten in Revista de oncología Barcelona : Doyma, 2000 13(2011), 10 vom: Okt., Seite 753-759 (DE-627)385985452 (DE-600)2143451-7 1578-195X nnns volume:13 year:2011 number:10 month:10 pages:753-759 https://dx.doi.org/10.1007/s12094-011-0728-4 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 13 2011 10 10 753-759 |
language |
English |
source |
Enthalten in Revista de oncología 13(2011), 10 vom: Okt., Seite 753-759 volume:13 year:2011 number:10 month:10 pages:753-759 |
sourceStr |
Enthalten in Revista de oncología 13(2011), 10 vom: Okt., Seite 753-759 volume:13 year:2011 number:10 month:10 pages:753-759 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Rectal cancer Molecular changes Neoadjuvant therapy |
dewey-raw |
610 |
isfreeaccess_bool |
false |
container_title |
Revista de oncología |
authorswithroles_txt_mv |
Hughes, Rebecca @@aut@@ Parry, James @@aut@@ Beynon, John @@aut@@ Jenkins, Gareth @@aut@@ |
publishDateDaySort_date |
2011-10-01T00:00:00Z |
hierarchy_top_id |
385985452 |
dewey-sort |
3610 |
id |
SPR024256722 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR024256722</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519111106.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2011 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12094-011-0728-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR024256722</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12094-011-0728-4-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hughes, Rebecca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Molecular changes consistent with increased proliferation and invasion are common in rectal cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2011</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Rectal cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Molecular changes</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoadjuvant therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Parry, James</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Beynon, John</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jenkins, Gareth</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Revista de oncología</subfield><subfield code="d">Barcelona : Doyma, 2000</subfield><subfield code="g">13(2011), 10 vom: Okt., Seite 753-759</subfield><subfield code="w">(DE-627)385985452</subfield><subfield code="w">(DE-600)2143451-7</subfield><subfield code="x">1578-195X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2011</subfield><subfield code="g">number:10</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:753-759</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12094-011-0728-4</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2011</subfield><subfield code="e">10</subfield><subfield code="c">10</subfield><subfield code="h">753-759</subfield></datafield></record></collection>
|
author |
Hughes, Rebecca |
spellingShingle |
Hughes, Rebecca ddc 610 misc Rectal cancer misc Molecular changes misc Neoadjuvant therapy Molecular changes consistent with increased proliferation and invasion are common in rectal cancer |
authorStr |
Hughes, Rebecca |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)385985452 |
format |
electronic Article |
dewey-ones |
610 - Medicine & health |
delete_txt_mv |
keep |
author_role |
aut aut aut aut |
collection |
springer |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
1578-195X |
topic_title |
610 ASE Molecular changes consistent with increased proliferation and invasion are common in rectal cancer Rectal cancer (dpeaa)DE-He213 Molecular changes (dpeaa)DE-He213 Neoadjuvant therapy (dpeaa)DE-He213 |
topic |
ddc 610 misc Rectal cancer misc Molecular changes misc Neoadjuvant therapy |
topic_unstemmed |
ddc 610 misc Rectal cancer misc Molecular changes misc Neoadjuvant therapy |
topic_browse |
ddc 610 misc Rectal cancer misc Molecular changes misc Neoadjuvant therapy |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Revista de oncología |
hierarchy_parent_id |
385985452 |
dewey-tens |
610 - Medicine & health |
hierarchy_top_title |
Revista de oncología |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)385985452 (DE-600)2143451-7 |
title |
Molecular changes consistent with increased proliferation and invasion are common in rectal cancer |
ctrlnum |
(DE-627)SPR024256722 (SPR)s12094-011-0728-4-e |
title_full |
Molecular changes consistent with increased proliferation and invasion are common in rectal cancer |
author_sort |
Hughes, Rebecca |
journal |
Revista de oncología |
journalStr |
Revista de oncología |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology |
recordtype |
marc |
publishDateSort |
2011 |
contenttype_str_mv |
txt |
container_start_page |
753 |
author_browse |
Hughes, Rebecca Parry, James Beynon, John Jenkins, Gareth |
container_volume |
13 |
class |
610 ASE |
format_se |
Elektronische Aufsätze |
author-letter |
Hughes, Rebecca |
doi_str_mv |
10.1007/s12094-011-0728-4 |
dewey-full |
610 |
author2-role |
verfasserin |
title_sort |
molecular changes consistent with increased proliferation and invasion are common in rectal cancer |
title_auth |
Molecular changes consistent with increased proliferation and invasion are common in rectal cancer |
abstract |
Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer. |
abstractGer |
Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer. |
abstract_unstemmed |
Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 |
container_issue |
10 |
title_short |
Molecular changes consistent with increased proliferation and invasion are common in rectal cancer |
url |
https://dx.doi.org/10.1007/s12094-011-0728-4 |
remote_bool |
true |
author2 |
Parry, James Beynon, John Jenkins, Gareth |
author2Str |
Parry, James Beynon, John Jenkins, Gareth |
ppnlink |
385985452 |
mediatype_str_mv |
c |
isOA_txt |
false |
hochschulschrift_bool |
false |
doi_str |
10.1007/s12094-011-0728-4 |
up_date |
2024-07-04T00:11:19.406Z |
_version_ |
1803605119504220160 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR024256722</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519111106.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201006s2011 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12094-011-0728-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR024256722</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12094-011-0728-4-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hughes, Rebecca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Molecular changes consistent with increased proliferation and invasion are common in rectal cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2011</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Survival in rectal cancer remains unchanged despite improved treatment modalities. Molecular biology may hold the key to new strategies. Gene expression abnormalities need identification in tumour specimens to identify targets for therapy. The impact of neoadjuvant therapy on induced gene expression changes needs to be assessed to distinguish the intrinsic tumour-specific changes from those changes that may be induced by neoadjuvant therapy. Methods Gene expression changes were examined in 21 rectal tumours plus matched normal mucosa and cells exposed to 5-FU and gamma radiation, using DNA membrane arrays. These arrays contained 100 genes in common cancer pathways. The most commonly up-regulated gene, c-FOS, was quantified using real-time PCR. Results c-FOS was the most commonly up-regulated gene, occurring in 7 of 21 samples (33%), all samples having a greater than 2-fold increase. SERPINE-1 was the second most commonly up-regulated gene with 6 of 21 samples showing up-regulation (29%). There was no clear correlation between up-regulation of c-FOS or SERPINE-1 and clinico-pathological data. Neither c-FOS nor SERPINE-1 gene expression was induced by 5-FU treatment or gamma irradiation in vitro, but MUC 18 was up-regulated by 5-FU treatment. This suggests that FOS and SERPINE-1 expression changes are specific to the tumour and will not arise as artefacts of neoadjuvant therapy. Conclusion The study suggests that c-FOS and SERPINE-1 may have important but as yet unclear roles in the tumour biology of rectal cancer but probably only represent a small part of the complex molecular biology of rectal cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Rectal cancer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Molecular changes</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoadjuvant therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Parry, James</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Beynon, John</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jenkins, Gareth</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Revista de oncología</subfield><subfield code="d">Barcelona : Doyma, 2000</subfield><subfield code="g">13(2011), 10 vom: Okt., Seite 753-759</subfield><subfield code="w">(DE-627)385985452</subfield><subfield code="w">(DE-600)2143451-7</subfield><subfield code="x">1578-195X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2011</subfield><subfield code="g">number:10</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:753-759</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12094-011-0728-4</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2011</subfield><subfield code="e">10</subfield><subfield code="c">10</subfield><subfield code="h">753-759</subfield></datafield></record></collection>
|
score |
7.400074 |